Use of Pancreatic Xenograft Models for Evaluating Targeted Therapies

Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest malignancies, driven by a complex interplay of oncogenic KRAS signaling, stromal desmoplasia, and immunosuppressive microenvironments. Evaluating targeted therapies in PDAC demands preclinical models that replicate these features. Orthotopic pancreatic xenografts established by Altogen Labs using human PDAC cell lines allow accurate assessment of anti-KRAS, anti-MEK, and immunomodulatory agents. For instance, orthotopic PANC-1 xenografts exhibit dense fibrotic stroma composed of activated pancreatic stellate cells (α-SMA positive) and collagen I deposition, as shown by immunofluorescence and Second Harmonic Generation microscopy. This microenvironment fosters resistance to conventional chemotherapy and targeted treatments.

Altogen Labs recently conducted a study examining a novel MEK inhibitor (MEKi-28) in PANC-1 orthotopic xenografts. MEKi-28 at 25 mg/kg daily oral gavage produced a 55% reduction in tumor volume over three weeks, compared with vehicle controls (p<0.01). Immunohistochemical analysis of harvested tumors revealed decreased pERK (phosphorylated ERK) signaling and reduced Ki-67 labeling by 60%. Additionally, Masson’s trichrome staining showed a modest 20% reduction in collagen deposition, suggesting partial stromal modulation. To address the desmoplastic barrier, Altogen’s Pancreas In Vivo Transfection Kit was employed to deliver siRNA targeting α-Smooth Muscle Actin (α-SMA) to orthotopic tumors, achieving >65% knockdown at 48 hours post-injection (qRT-PCR normalized to 18S rRNA). Combining MEKi-28 with α-SMA siRNA resulted in a synergistic 75% tumor reduction and a 45% decrease in microvessel density (quantified by CD31 immunostaining), indicating enhanced drug penetration and anti-angiogenic effects.

Moreover, orthotopic xenografts facilitate immunotherapy evaluations by preserving tumor-associated macrophages (TAMs) and myeloid-derived suppressor cells (MDSCs). In Capan-1 orthotopic models, co-administration of checkpoint blockade monoclonal antibodies (anti-PD-1 and anti-CTLA-4) with nanoparticle-delivered mRNA encoding tumor antigens increased CD8⁺ T cell infiltration by 3-fold, as measured by flow cytometry of CD3⁺CD8⁺ populations. Tumor growth slowed by 50% compared to checkpoint blockade alone (p<0.01). These studies illustrate how Altogen Labs’ integrated transfection and xenograft platforms enable comprehensive evaluation of targeted and immune-based therapies in a physiologically relevant PDAC context.